Impute.me: an open source, non-profit tool for using data from DTC genetic testing to calculate and interpret polygenic risk scores.
Lasse FolkerseniD, Oliver PainiD, Andrés IngasoniD, Thomas Mears WergeiD, Cathryn M. LewisiD, Jehannine AustiniD
Abstract
To date, interpretation of genomic information has focused on single variants conferring disease risk, but most disorders of major public concern have a polygenic architecture. Polygenic risk scores (PRS) give a single measure of disease liability by summarising disease risk across hundreds of thousands of genetic variants. They can be calculated in any genome-wide genotype data-source, using a prediction model based on genome-wide summary statistics from external studies. As genome-wide association studies increase in power, the predictive ability for disease risk will also increase. While PRS are unlikely ever to be fully diagnostic, they may give valuable medical information for risk stratification, prognosis, or treatment response prediction. Public engagement is therefore becoming important on the potential use and acceptability of PRS. However, the current public perception of genetics is that it provides Yes/No answers about the presence/absence of a condition, or the potential for developing a condition, which in not the case for common, complex disorders with of polygenic architecture. Meanwhile, unregulated third-party applications are being developed to satisfy consumer demand for information on the impact of lower risk variants on common diseases that are highly polygenic. Often applications report results from single SNPs and disregard effect size, which is highly inappropriate for common, complex disorders where everybody carries risk variants. Tools are therefore needed to communicate our understanding of genetic predisposition as a continuous trait, where a genetic liability confers risk for disease. Impute.me is one such a tool, whose focus is on education and information on common, complex disorders with polygenetic architecture. Its research-focused open-source website allows users to upload consumer genetics data to obtain PRS, with results reported on a population-level normal distribution. Diseases can only be browsed by ICD10-chapter-location or alphabetically, thus prompting the user to consider genetic risk scores in a medical context of relevance to the individual. Here we present an overview of the implementation of the impute.me site, along with analysis of typical usage-patterns, which may advance public perception of genomic risk and precision medicine.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 67
- FWCI
- 7.33
- Field percentile
- top 2%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PRS-on-Spark: a novel, efficient and flexible approach for generating polygenic risk scores
Lawrence M. Chen, Nelson Yao, … Kieran J. O’Donnell·BMC BioinformaticsPeer-reviewed·Aug 8, 2018
- A Qualitative Study Exploring the Consumer Experience of Receiving Self-Initiated Polygenic Risk Scores from a Third-Party Website
Kiara Lowes, Kennedy J. Borle, … Jehannine Austin·European Journal of Human GeneticsPeer-reviewed·Oct 4, 2022
- Improving reporting standards for polygenic scores in risk prediction studies
Hannah Wand, Samuel A. Lambert, … Genevieve L. Wojcik·NaturePeer-reviewed·Mar 10, 2021
- Private Information Leakage from Polygenic Risk Scores
Kirill Nikitin, Gamze Gürsoy·Genome ResearchPeer-reviewed·Aug 17, 2026
- The predictive capacity of polygenic risk scores for disease risk is only moderately influenced by imputation panels tailored to the target population
Hagai Levi, Ran Elkon, Ron Shamir A·BioinformaticsPeer-reviewed·Jan 20, 2024
- Positioning Personal Polygenic Risk score against the population background.
Ganna Leonenko, Emily Ann Baker, … the Alzheimer’s Disease Neuroimaging Initiative·bioRxiv·Oct 24, 2019